GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (NAS:MREO) » Definitions » Deferred Policy Acquisition Costs

Mereo BioPharma Group (Mereo BioPharma Group) Deferred Policy Acquisition Costs


View and export this data going back to 2018. Start your Free Trial

What is Mereo BioPharma Group Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Mereo BioPharma Group (Mereo BioPharma Group) Business Description

Traded in Other Exchanges
Address
One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its oncology product candidate is etigilimab, for patients with solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.